Literature DB >> 34676938

Imaging Blood-Brain Barrier Permeability Through MRI in Pediatric Sickle Cell Disease: A Feasibility Study.

Zixuan Lin1, Eboni Lance2,3, Tiffany McIntyre2, Yang Li1, Peiying Liu1, Chantelle Lim1,4, Hongli Fan1,4, Aylin Tekes1, Alicia Cannon5, James F Casella6, Hanzhang Lu1,4,7.   

Abstract

BACKGROUND: Blood-brain barrier (BBB) disruption may lead to endothelium dysfunction and inflammation in sickle cell disease (SCD). However, abnormalities of BBB in SCD, especially in pediatric patients for whom contrast agent administration less than optimal, have not been fully characterized.
PURPOSE: To examine BBB permeability to water in a group of pediatric SCD participants using a non-invasive magnetic resonance imaging technique. We hypothesized that SCD participants will have increased BBB permeability. STUDY TYPE: Prospective cross-sectional. POPULATION: Twenty-six pediatric participants (10 ± 1 years, 15F/11M) were enrolled, including 21 SCD participants and 5 sickle cell trait (SCT) participants, who were siblings of SCD patients. FIELD STRENGTH/SEQUENCE: 3 T. Water extraction with phase-contrast arterial spin tagging with echo-planer imaging, phase-contrast and T1 -weighted magnetization-prepared rapid acquisition of gradient echo. ASSESSMENT: Water extraction fraction (E), BBB permeability-surface area product (PS), cerebral blood flow, hematological measures (hemoglobin, hematocrit, hemoglobin S), neuropsychological scores (including domains of intellectual ability, attention and executive function, academic achievement and adaptive function, and a composite score). Regions of interest were drawn by Z.L. (6 years of experience). STATISTICAL TESTS: Wilcoxon rank sum test and chi-square test for group comparison of demographics. Multiple linear regression analysis of PS with diagnostic category (SCD or SCT), hematological measures, and neuropsychological scores. A two-tailed P value of 0.05 or less was considered statistically significant.
RESULTS: Compared with SCT participants, SCD participants had a significantly higher BBB permeability to water (SCD: 207.0 ± 33.3 mL/100 g/minute, SCT: 171.2 ± 27.2 mL/100 g/minute). SCD participants with typically more severe phenotypes also had a significantly leakier BBB than those with typically milder phenotypes (severe: 217.3 ± 31.7 mL/100 g/minute, mild: 193.3 ± 31.8 mL/100 g/minute). Furthermore, more severe BBB disruption was associated with worse hematological symptoms, including lower hemoglobin concentrations (β = -8.84, 95% confidence interval [CI] [-14.69, -3.00]), lower hematocrits (β = -2.96, 95% CI [-4.84, -1.08]), and higher hemoglobin S fraction (β = 0.77, 95% CI [0.014, 1.53]). DATA
CONCLUSION: These findings support a potential role for BBB dysfunction in SCD pathogenesis of ischemic injury. LEVEL OF EVIDENCE: 2 TECHNICAL EFFICACY: Stage 2.
© 2021 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  WEPCAST MRI; blood-brain barrier; pediatric; sickle cell disease; water exchange

Mesh:

Substances:

Year:  2021        PMID: 34676938      PMCID: PMC9018466          DOI: 10.1002/jmri.27965

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   5.119


  34 in total

1.  Determining the longitudinal relaxation time (T1) of blood at 3.0 Tesla.

Authors:  Hanzhang Lu; Chekesha Clingman; Xavier Golay; Peter C M van Zijl
Journal:  Magn Reson Med       Date:  2004-09       Impact factor: 4.668

2.  Diffusion sensitivity of 3D-GRASE in arterial spin labeling perfusion.

Authors:  Xiang He; Kenneth Wengler; Mark E Schweitzer
Journal:  Magn Reson Med       Date:  2018-01-07       Impact factor: 4.668

3.  Risk Factors for Attention and Behavioral Issues in Pediatric Sickle Cell Disease.

Authors:  Eboni I Lance; Anne M Comi; Michael V Johnston; James F Casella; Bruce K Shapiro
Journal:  Clin Pediatr (Phila)       Date:  2015-07-06       Impact factor: 1.168

Review 4.  Pathophysiology and treatment of stroke in sickle-cell disease: present and future.

Authors:  Jeffrey A Switzer; David C Hess; Fenwick T Nichols; Robert J Adams
Journal:  Lancet Neurol       Date:  2006-06       Impact factor: 44.182

5.  Co-Occurrence of Neurodevelopmental Disorders in Pediatric Sickle Cell Disease.

Authors:  Eboni I Lance; Alicia D Cannon; Bruce K Shapiro; Li-Ching Lee; Michael V Johnston; James F Casella
Journal:  J Dev Behav Pediatr       Date:  2021-08-01       Impact factor: 2.988

6.  Spatiotemporal dysfunction of the vascular permeability barrier in transgenic mice with sickle cell disease.

Authors:  Samit Ghosh; Fang Tan; Solomon F Ofori-Acquah
Journal:  Anemia       Date:  2012-06-12

7.  Mapping water exchange across the blood-brain barrier using 3D diffusion-prepared arterial spin labeled perfusion MRI.

Authors:  Xingfeng Shao; Samantha J Ma; Marlene Casey; Lina D'Orazio; John M Ringman; Danny J J Wang
Journal:  Magn Reson Med       Date:  2018-12-18       Impact factor: 3.737

8.  Regional oxygen extraction predicts border zone vulnerability to stroke in sickle cell disease.

Authors:  Melanie E Fields; Kristin P Guilliams; Dustin K Ragan; Michael M Binkley; Cihat Eldeniz; Yasheng Chen; Monica L Hulbert; Robert C McKinstry; Joshua S Shimony; Katie D Vo; Allan Doctor; Hongyu An; Andria L Ford; Jin-Moo Lee
Journal:  Neurology       Date:  2018-03-02       Impact factor: 11.800

9.  Noncontrast assessment of blood-brain barrier permeability to water: Shorter acquisition, test-retest reproducibility, and comparison with contrast-based method.

Authors:  Zixuan Lin; Dengrong Jiang; Dapeng Liu; Yang Li; Jinsoo Uh; Xirui Hou; Jay J Pillai; Qin Qin; Yulin Ge; Hanzhang Lu
Journal:  Magn Reson Med       Date:  2021-02-08       Impact factor: 3.737

10.  Non-invasive MRI of brain clearance pathways using multiple echo time arterial spin labelling: an aquaporin-4 study.

Authors:  Yolanda Ohene; Ian F Harrison; Payam Nahavandi; Ozama Ismail; Eleanor V Bird; Ole P Ottersen; Erlend A Nagelhus; David L Thomas; Mark F Lythgoe; Jack A Wells
Journal:  Neuroimage       Date:  2018-12-15       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.